Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peri-operative physostigmine prophylaxis in liver resection patients at risk for delirium and postoperative cognitive dysfunction
ISRCTN18978802Phase 4Completed
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Aug 2009
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in delirium and post-operative cognitive decline (POCD) comparing Physostigmine with Placebo (2 arms). Primary endpoints: Postoperative delirium by DSM-IV and Postoperative cognitive dysfunction by CANTAB. Started Aug 2009; status: completed.
02
Drugs
physostigmine
03
Conditions
deliriumpost-operative cognitive decline (POCD)
Beyond the preview
Go deeper on ISRCTN18978802.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN18978802.